NeurAxis, Inc.
NYSE American NRXS
NeurAxis, Inc. Price to Sales Ratio (P/S) on January 14, 2025: 7.16
NeurAxis, Inc. Price to Sales Ratio (P/S) is 7.16 on January 14, 2025, a 108.91% change year over year. Price to sales ratio compares the stock price to the sales per share; higher suggests positive sentiment for future revenue growth.
-
NeurAxis, Inc. 52-week high Price to Sales Ratio (P/S) is 9.60 on September 04, 2024, which is 34.01% above the current Price to Sales Ratio (P/S).
-
NeurAxis, Inc. 52-week low Price to Sales Ratio (P/S) is 3.01 on January 23, 2024, which is -57.94% below the current Price to Sales Ratio (P/S).
-
NeurAxis, Inc. average Price to Sales Ratio (P/S) for the last 52 weeks is 6.93.
Key data
| Date | Price to Sales Ratio (P/S) | Price to Book Ratio (P/B) | Dividend Yield | Free Cash Flow Yield |
|---|
Market news
Loading...
NYSE American: NRXS
| CEO | Mr. Brian Carrico |
| IPO Date | Aug. 9, 2023 |
| Location | United States |
| Headquarters | 11550 North Meridian Street |
| Employees | 19 |
| Sector | Health Care |
| Industries | |
Description
NeurAxis, Inc. operates as a neuromodulation therapy device company in the United States. It offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 11-18 years of age with functional abdominal pain associated with irritable bowel syndrome healthcare companies primarily hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. The company was founded in 2011 and is headquartered in Carmel, Indiana.
Key trends
Past 5 years
StockViz Staff
January 15, 2025
Any question? Send us an email